RADAR study

Although antipsychotics are effective at reducing psychotic symptoms and relapse in the short-term, long-term effects remain uncertain.

Therefore the National Institute of Health Research has funded a randomised trial to assess the benefits and risks of a flexible, supported strategy for antipsychotic dose reduction and discontinuation where possible, in people with schizophrenia and non-affective psychosis.

Participants will be randomised to have the antipsychotic reduction treatment or to continue with antipsychotic maintenance treatment.

Participants

We are looking for participants who fulfil the following criteria:

  • A diagnosis of schizophrenia, schizoaffective disorder, delusional disorder or non-affective psychosis
  • Over 18 years old
  • More than one episode or a single episode lasting over a year
  • Taking antipsychotics.

Exclusion criteria are:

  • Participant has required acute care by the crisis team or inpatient unit in the last month
  • Being on a Supervised Community Treatment Order of the Mental Health Act
  • A serious risk of harm to self or others
  • Being pregnant or breast feeding.

Patients who decide to take part will be interviewed by the research team at baseline, six months, 12 months and 24 months, in which they will be asked questions about their mental health. We hope that we can also follow people up for longer in the future (at four or five years, for example), as more data on long-term outcomes is really important.

For further information please contact

Roberta Box
Tel: 07500 920737
Email: roberta.box@nhs.net

http://www.ucl.ac.uk/psychiatry/antipsychotic-discontinuation-and-reduction

Or click her to complete our online form